Vasculature-disrupting Strategies Combined with Bacterial Spores Targeting Hypoxic Regions of Solid Tumors

Vascular-Targeted Therapies in Oncology

Volumn , Issue , 2006, Pages 261-276

  Ahn, G One ^a   Martin Brown, J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADEPT (antibody directed) and GDEPT (gene directed); CDEPT and vascular disrupting agents; CDEPT in combination with DMXAA; Clostridia as hypoxia necrotic selective cancer therapy; Clostridial approach to enzyme prodrug therapy (CDEPT); Hypoxic necrotic area and human solid tumor; Optimizing prodrug design; Vascular disrupting agents and genetically engineered anaerobic bacteria; Vasculature disrupting strategies

Indexed keywords

EID: 33846217088     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470035439.ch15     Document Type: Chapter

References (54)

1. Ahn, G., Liu, S.C., Menke, D., Dorie, M.J. and Brown, J.M. (2004). Enhanced antitumor activity of 5-FC by genetically engineered anaerobic bacteria C. sporogenes expressing cytosine deaminase when combined with a vascular targeting agent, ZD6126 or DMXAA. In 2nd International Conference on Vascular Targeting, Miami, FL.
2. Baguley, B.C. and Ching, L.M. (2002). DMXAA: an antivascular agent with multiple host responses. Int J Radiat Oncol Biol Phys 54, 1503-1511.
3. Becker, A., Hansgen, G., Bloching, M., Weigel, C., Lautenschlager, C. and Dunst, J. (1998). Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 42, 35-41.
4. Blakey, D.C., Westwood, F.R., Walker, M., Hughes, G.D., Davis, P.D., Ashton, S.E. and Ryan, A.J. (2002). Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8, 1974-1983.
5. Brizel, D.M., Dodge, R.K., Clough, R.W. and Dewhirst, M.W. (1999). Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53, 113-117.
6. Brizel, D.M., Rosner, G.L., Prosnitz, L.R. and Dewhirst, M.W. (1995). Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas, and lymph node metastases. Int J Radiat Oncol Biol Phys 32, 1121-1125.
7. Brown, J.M. and Giaccia, A.J. (1998). The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58, 1408-1416.
8. Brown, J.M. and Wilson, W.R. (2004). Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4, 437-447.
9. Carey, R.W., Holland, J.F., Whang, H.Y., Neter, E. and Bryant, B. (1967). Clostridial oncolysis in man. Eur J Cancer 3, 37-46.
10. Ching, L.M., Cao, Z., Kieda, C., Zwain, S., Jameson, M.B. and Baguley, B.C. (2002). Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86, 1937-1942.
11. Dang, L.H., Bettegowda, C., Huso, D.L., Kinzler, K.W. and Vogelstein, B. (2001). Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci USA 98, 15155-15160.
12. Denny, W.A. (2003). Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J Biomed Biotechnol 2003, 48-70.
13. Engelbart, K. and Gericke, D. (1964). Oncolysis by Clostridia. V. Transplanted tumors of the hamster. Cancer Res 24, 239-243.
14. Fabricius, E.M., Schneeweiss, U., Schau, H.P., Schmidt, W. and Benedix, A. (1993). Quantitative investigations into the elimination of in vitro-obtained spores of the non-pathogenic Clostridium butyricum strain CNRZ 528, and their persistence in organs of different species following intravenous spore administration. Res Microbiol 144, 741-753.
15. Fox, M.E., Lemmon, M.J., Mauchline, M.L., Davis, T.O., Giaccia, A.J., Minton, N.P. and Brown, J.M. (1996). Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fl uorocytosine by genetically engineered clostridia. Gene Ther 3, 173-178.
16. Gericke, D., Dietzel, F., Konig, W., Ruster, I. and Schumacher, L. (1979). Further progress with oncolysis due to apathogenic clostridia. Zentralb Bakteriol [Orig A] 243, 102-112.
17. Goertz, D.E., Yu, J.L., Kerbel, R.S., Burns, P.N. and Foster, F.S. (2002). High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood fl ow. Cancer Res 62, 6371-6375.
18. Goto, H., Yano, S., Zhang, H., Matsumori, Y., Ogawa, H., Blakey, D.C. and Sone, S. (2002). Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 62, 3711-3715.
19. Graeber, T.G., Osmanian, C., Jacks, T., Housman, D.E., Koch, C.J., Lowe, S.W. and Giaccia, A.J. (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379, 88-91.
20. Harris, A.L. (2002). Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2, 38-47.
21. Heppner, F. and Mose, J.R. (1978). The liquefaction (oncolysis) of malignant gliomas by a non pathogenic clostridium. Acta Neurol 12, 123-125.
22. Heppner, F., Mose, J., Ascher, P.W. and Walter, G. (1983). 13th Int Congr Chemother 226, 38-45.
23. Horsman, M.R. and Murata, R. (2003). Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 57, 1047-1055.
24. Huang, J., Frischer, J.S., Serur, A., Kadenhe, A., Yokoi, A., McCrudden, K.W., New, T., O'Toole, K., Zabski, S., Rudge, J.S., Holash, J., Yancopoulos, G.D., Yamashiro, D.J. and Kandel, J.J. (2003). Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 100, 7785-7790.
25. Kievit, E., Nyati, M.K., Ng, E., Stegman, L.D., Parsels, J., Ross, B.D., Rehemtulla, A. and Lawrence, T.S. (2000). Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fl uorocytosine of human colorectal cancer xenografts. Cancer Res 60, 6649-6655.
26. Koong, A.C., Mehta, V.K., Le, Q.T., Fisher, G.A., Terris, D.J., Brown, J.M., Bastidas, A.J. and Vierra, M. (2000). Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 48, 919-922.
27. Kuriyama, S., Masui, K., Sakamoto, T., Nakatani, T., Kikukawa, M., Tsujinoue, H., Mitoro, A., Yamazaki, M., Yoshiji, H., Fukui, H., Ikenaka, K., Mullen, C.A. and Itsujii, T. (1998). Bystander effect caused by cytosine deaminase gene and 5-fl uorocytosine in vitro is subtantially mediated by generated 5-fl uorouracil. Anticancer Res 18, 3399-3406.
28. Lemmon, M.J., Elwell, J.H., Brehm, J.K., Mauchline, M.L., N, M., Minton, N.P., Giaccia, A.J. and Brown, J.M. (1994). Anaerobic bacteria as a gene delivery system to tumors. Proc Am Assoc Cancer Res 35, 374.
29. Lemmon, M.L., Van Zijl, P., Fox, M.E., Mauchline, M.L., Giaccia, A.J., Minton, N.P. and Brown, J.M. (1997). Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther 4, 791-796.
30. Liu, S.C., Minton, N.P., Giaccia, A.J. and Brown, J.M. (2002). Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther 9, 291-296.
31. Longley, D.B., Harkin, P. and Johnston, P.G. (2003). 5-fl uorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3, 330-338.
32. Malmgren, R.A. and Flanigan, C.C. (1955). Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res 15, 473-478.
33. Martin, J., Stribbling, S.M., Poon, G.K., Begent, R.H., Napier, M., Sharma, S.K. and Springer, C.J. (1997). Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol 40, 189-201.
34. Melton, R.G. and Sherwood, R.F. (1996). Antibody-enzyme conjugates for cancer therapy. J Natl Cancer Inst 88, 153-165.
35. Mose, J.R. and Mose, G. (1959). Onkolyseversuche mit apathogenen anaeroben Sporenbildern am Ehrlich Tumor des Maus. Z Krebsforsch 63, 63-74.
36. Mose, J.R. and Mose, G. (1964). Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res 24, 212-216.
37. Movsas, B., Chapman, J.D., Horwitz, E.M., Pinover, W.H., Greenberg, R.E., Hanlon, A.L., Iyer, R. and Hanks, G.E. (1999). Hypoxic regions exist in human prostate carcinoma. Urology 53, 11-18.
38. Murata, R., Siemann, D.W., Overgaard, J. and Horsman, M.R. (2001). Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 156, 503-509.
39. Nuyts, S., Van Mellaert, L., Theys, J., Landuyt, W., Lambin, P. and Anne, J. (2002). Clostridium spores for tumor-specific drug delivery. Anticancer Drugs 13, 115-125.
40. Pruijn, F.B., Sturman, J., Liyanage, S., Hicks, K.O., Hay, M.P. and Wilson, W.R. (2005). Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures. J Med Chem 48, 1079-1087.
41. Rampling, R., Cruickshank, G., Lewis, A.D., Fitzsimmons, S.A. and Workman, P. (1994). Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29, 427-431.
42. Robinson, S.P., McIntyre, D.J., Checkley, D., Tessier, J.J., Howe, F.A., Griffiths, J.R., Ashton, S.E., Ryan, A.J., Blakey, D.C. and Waterton, J.C. (2003). Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 88, 1592-1597.
43. Siemann, D.W., Mercer, E., Lepler, S. and Rojiani, A.M. (2002). Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99, 1-6.
44. Siemann, D.W. and Rojiani, A.M. (2002). Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 53, 164-171.
45. Siim, B.G., Lee, A.E., Shalal-Zwain, S., Pruijn, F.B., McKeage, M.J. and Wilson, W.R. (2003). Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51, 43-52.
46. Sundfor, K., Lyng, H., Kongsgard, U.L., Trope, C. and Rofstad, E.K. (1997). Polarographic measurement of pO2 in cervix carcinoma. Gynecol Oncol 64, 230-236.
47. Theys, J., Landuyt, W., Nuyts, S., Van Mellaert, L., Bosmans, E., Rijnders, A., Van Den Bogaert, W., van Oosterom, A., Anne, J. and Lambin, P. (2001). Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol Med Microbiol 30, 37-41.
48. Thiele, E.H., Arison, R.N. and Boxer, G.E. (1964). Oncolysis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumors. Cancer Res 24, 234-238.
49. Thomlinson, R.H. and Gray, L.H. (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9, 539-549.
50. Tietze, L.F., Lieb, M., Herzig, T., Haunert, F. and Schuberth, I. (2001). A strategy for tumorselective chemotherapy by enzymatic liberation of seco-duocarmycin SA-derivatives from nontoxic prodrugs. Bioorg Med Chem 9, 1929-1939.
51. Varghese, H.J., Mackenzie, L.T., Groom, A.C., Ellis, C.G., Ryan, A., MacDonald, I.C. and Chambers, A.F. (2004). In vivo videomicroscopy reveals differential effects of the vasculartargeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model. Angiogenesis 7, 157-164.
52. Vaupel, P.W. and Hockel, M. (1995). Oxygenation status of human tumors: a reappraisal using computerized pO2 histography. In Tumor Oxygenation (Ed. P.W. Vaupel, D.K. Kelleher and M. Gunderoth) Fischer, Stuttgart, pp. 219-232.
53. Wilson, W.R., Pullen, S.M., Hogg, A., Helsby, N.A., Hicks, K.O. and Denny, W.A. (2002). Quantitation of bystander effects in nitroreductase suicide gene therapy using threedimensional cell cultures. Cancer Res 6262, 1425-1432.
54. Wouters, B.G., Weppler, S.A., Koritzinsky, M., Landuyt, W., Nuyts, S., Theys, J., Chiu, R.K. and Lambin, P. (2002). Hypoxia as a target for combined modality treatments. Eur J Cancer 3838, 240-257.